Rigel Pharmaceuticals (RIGL) Tops Q3 Street Views
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) reports Q3 EPS of $0.96, versus the analyst estimate of $0.62. Revenue for the quarter was $72.3 million, which compares to the estimate of $55.78 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shake Shack (SHAK) IPO Opens Up 124%
- Doral Financial (DRL) Reports Modification to FHLB Facility; FDIC Issues Prompt Corrective Action Directive
- Chevron (CVX) Tops Q4 EPS Views
Create E-mail Alert Related CategoriesEarnings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!